CareDx Study Shows AlloSeq cfDNA Accurately Detects Organ Rejection

CareDx Study Shows AlloSeq cfDNA Accurately Detects Organ Rejection CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, announced new findings published in Transplant International. The study demonstrated that the performance of AlloSeq™ cfDNA in detecting allograft…










